[Proresid-methotrexate combination in chemotherapy of orofacial carcinoma].
D000380:Agranulocytosis / Q000139:chemically induced; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D007239:Infections; D007269:Injections, Intra-Arterial; D007970:Leukopenia / Q000139:chemically induced; D008048:Lip Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000188:drug therapy*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011033:Podophyllin / Q000627:therapeutic use; D011035:Podophyllum; D014062:Tongue Neoplasms / Q000188:drug therapy
D011033:Podophyllin; D008727:Methotrexate
Proresid-Methotrexate-Kombination in der Chemotherapie der orofacialen Carcinome.